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The depletion of CD8þ cells has been shown to prevent the
initiation and progression of antiglomerular basement
membrane (GBM) crescentic glomerulonephritis (GN) in
Wistar–Kyoto (WKY) rats. In this study, we asked whether
CD8þ cells produce their effects by perforin/granzyme-
mediated or by Fas ligand (FasL)-mediated pathways. The
glomerular mRNA expression of perforin and granzyme B
corresponded with the number of CD8þ cells, whereas that
of granzyme A, Fas, and FasL did not. The enhanced mRNA
level of perforin and granzyme B was not evident in CD8þ -
depleted rats. The number of apoptotic cells in the glomeruli
was significantly increased at day 3. Perforin mRNA was
found in cells infiltrating the glomerulus by in situ
hybridization and by using dual-staining
immunohistochemistry perforin protein was found in
glomerular CD8þ cells. We found that perforin was readily
visualized at the inner surface of the glomerular capillaries by
immunoelectron microscopy. Based on these results, we
treated animals with a perforin antibody in vivo and found
that it significantly reduced the amount of proteinuria,
frequency of crescentic glomeruli, and the number of
glomerular monocytes and macrophages, although the
number of glomerular CD8þ cells was not changed.
Our results suggest that CD8þ cells play a role in
glomerular injury as effector cells in part through a
perforin/granzyme-mediated pathway in the anti-GBM WKY
rat model of crescentic GN.
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In human crescentic glomerulonephritis (GN), both CD4-
and CD8-positive T lymphocytes are observed in glomer-
uli,1–3 often without deposition of humoral immune
mediators.4 In the pathogenesis of experimental crescentic
GN, the pivotal roles for cell-mediated immunity, especially T
helper 1 (Th1) immune responses have been strongly
suggested.5–7 In previous work, we showed a crucial role of
CD8þ cells (CD8þ ) in the initiation and the progression of
anti-glomerular basement membrane (GBM) crescentic GN
in Wistar–Kyoto (WKY) rats, without significant involvement
of humoral immune response and complement activation.8
This CD8-dependent model is characterized by a rapid
progression to renal failure with massive glomerular
accumulation of monocytes and macrophages (Mo/Mf,
ED-1þ cells) and a high frequency of crescent formation. The
unique features of this model may be due to the high
susceptibility of WKY rats to anti-GBM antibody compared
with other rat strains. Also in the accelerated form of anti-
GBM GN in WKY rats, the important role for CD8þ has
been demonstrated by the suppressive effect of the anti-CD8
antibody administration for both the prevention and the
treatment.9 The CD8þ have been considered to be involved
in glomerular injury indirectly by accumulating monocyte/
macrophages (Mo/Mf), as CD8þ are shown to upregulate
glomerular intercellular adhesion molecule-1 expression
through induction of cytokines.10 It has not been studied
about the potency of CD8þ to injure glomeruli directly as
local effector cells.
In general, CD8þ are known as cause target cell apoptosis
due to their cytotoxic actions, via perforin/granzyme-
mediated and/or Fas ligand (FasL)-mediated pathways,11–15
and may contribute to inflammatory immune responses in
some disease conditions. There are some in vivo studies
showing the positive correlation between the histological
severity and the increment of mRNA expressions of these
cytotoxic molecules. For example, in acute renal allograft
rejection, both mechanisms were operative and a direct
correlation was demonstrated between the histological
severity of the rejection and each of intrarenal mRNA
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expressions of FasL, Fas, granzyme B, and perforin.16 Also in
other forms of kidney disease, glomerular CD8þ accumula-
tion along with the glomerular mRNA expressions of
granzyme A and perforin was identified 8 weeks after the
induction of active Heymann nephritis.17 In the kidney of
NZB/W F1 lupus mice, the perforin mRNA expression was
significantly increased with age, which was ameliorated with
methylpredonisolone.18 In in vitro study, it was shown that
T-cell clones that were cytotoxic to cultured proximal renal
tubular epithelial cells expressed granzyme B and C, and that
an antisense oligonucleotide against granzyme C inhibited
the cytotoxicity.19 However, none of these studies has
presented the direct evidence of the perforin/granzyme-
mediated or the FasL-mediated renal injury in crescentic GN
by in vivo blocking of these cytotoxic molecules.
In this study, the role for perforin in CD8þ was studied in
anti-GBM crescentic GN in WKY rats. First, we examined the
glomerular mRNA expressions of perforin and granzyme A,
B, and the localization of perforin mRNA and protein in
glomerular infiltrating cells. Next, in vivo blocking of perforin
by antibody administration was carried out during the early
stages of this GN in order to ascertain the role perforin plays
in the glomerular injury.
RESULTS
Anti-GBM GN with or without anti-CD8 antibody adminis-
tration
A marked infiltration of mononuclear cells was obvious at
day 3 after anti-GBM antibody administration. At day 7,
crescent formation was observed in most of the glomeruli. By
immunofluorescence microscopy, a lot of ED-1þ Mo/Mf
were observed in glomeruli at day 3 and more at day 7, and
the number of glomerular CD8þ was slightly increased at
day 1, peaked at day 3 and decreased at day 7 as we reported
previously.8,10 In MRC-OX8 administrated rats, no CD8þ
were detected in the glomeruli at 1 h and days 1 and 3, but
only a few CD8þ were counted at day 7. Rabbit
immunoglobulin G (IgG) was localized along the GBM in a
linear pattern intensely at 1 h, and the intensity of
fluorescence was unchanged throughout the experiment.
The intensity of rat IgG in glomeruli was negligible or faint in
all time points.
Quantitation of glomerular mRNA for perforin, granzyme A,
B, Fas, and FasL
By ribonuclease protection assay, perforin and granzyme B
mRNAs were not detected in the normal rat glomerulus.
Both of them were expressed slightly at day 1, greatly
increased at day 3, and decreased at day 7, which
corresponded with the number of glomerular CD8þ . The
depletion of CD8þ resulted in the complete suppression of
perforin and granzyme B mRNAs at days 1 and 3 (Figure 1a),
with small amounts of the mRNAs appearing at day 7 when
the small number of CD8þ was found. Granzyme A mRNA
was not detected throughout the experimental period (data
not shown). Fas and FasL mRNAs were also increased in the
glomerulus after anti-GBM antibody administration, peaked
at day 1 and decreased afterwards, which did not correspond
with the number of glomerular CD8þ (Figure 1b).
Detection of apoptosis by TUNEL method
Although none or only a few terminal deoxynucleotidyl
transferase-mediated digoxigenin-deoxyuridine triphosphate
nick end labelling (TUNEL)-positive apoptotic cells were
observed in normal glomeruli (0.1070.06 cells/glomerular
cross-section (gcs)) and at day 1 (0.8070.18 cells/gcs)
(Figure 2a), the number of apoptotic cells in glomeruli was
significantly increased at day 3 (7.4370.74 cells/gcs, Po0.01)
(Figure 2b), and reduced at day 7 (3.0070.52 cells/gcs)
(Figure 2c).
Localization of perforin mRNA and protein
Perforin protein and mRNA were demonstrated in glomeruli
at day 3, by immunohistochemistry (Figure 3b) and in situ
hybridization (Figure 3d), respectively. The protein staining
and mRNA grains were most prominent on the cells that
appeared to be infiltrating mononuclear cells. Immunohis-
tochemistry using sequential serial sections for CD8þ
(Figure 4a) and perforin (Figure 4b) revealed that most of
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Figure 1 | Ribonuclease protection assay. (a) Representative
glomerular mRNA expressions of perforin and granzyme B, (b) and
Fas and FasL. (a) Both perforin and granzyme B mRNA expressions
were not detected in normal glomeruli. Weak but significant
expressions were found at day 1, intense expression at day 3, and
weak expression at day 7. In CD8þ -depleted rats, both were
completely suppressed at day 1 and day 3, and were only weakly
detected at day 7 when a few CD8þ appeared. (b) Intense
expressions of Fas and FasL mRNA in glomeruli were found at day 1,
and both were decreased afterwards, which did not correspond with
the number of glomerular CD8þ .
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the perforin-positive cells in glomeruli were considered to be
CD8þ . And Dual-staining immunohistochemistry (Figure
4e) confirmed that the perforin protein was localized in the
CD8þ . Immunoelectron microscopy (Figure 5) revealed that
perforin was localized in the cytoplasmic granules of
glomerular infiltrating lymphocyte (square-1). Also, perforin
released outside was demonstrated at the inner surface of the
glomerular capillaries (square-2), where the structure of
endothelial cell was obscure.
In vivo blocking of perforin in anti-GBM GN
Urinary protein excretion. All rats that received anti-GBM
antibody excreted significant amount of urinary protein. The
amount was significantly decreased from 23.077.0 mg/day
(day 3), 61.073.0 mg/day (day 5), and 45.071.2 mg/day
(day 7) in control group, to 6.271.4 mg/day (day 3,
Po0.01), 6.670.4 mg/day (day 5, Po0.01), and
4.270.2 mg/day (day 7, Po0.01) in the anti-perforin anti-
body group, respectively. The amounts at day 3, 5, 7 in anti-
perforin antibody group were all comparable with the
amount of normal rats (5.472.0 mg/day, NS).
Histology. The frequency of crescentic glomeruli was
dramatically decreased at day 7 from 85.075.0% (preim-
mune serum-injected group, Figure 6a) to 15.073.0% (anti-
perforin antibody-treated group, Figure 6b) (Po0.01). The
number of glomerular ED-1þ Mo/Mf was apparently
reduced by the anti-perforin antibody treatment, from
26.373.1 cells/gcs (preimmune serum group, Figure 6c) to
7.571.2 cells/gcs (anti-perforin antibody group, Figure 6d)
(Po0.01). In contrast, the number of glomerular CD8þ was
not changed by the anti-perforin antibody treatment;
7.771.4 cells/gcs (preimmune serum-injected group) and
7.571.6 cells/gcs (anti-perforin antibody-treated group)
(NS). Rabbit IgG was localized along the GBM in a linear
pattern intensely throughout the experiment, and the
intensity was not changed by the administration of anti-
perforin antibody in all time points. And the intensity of rat
IgG in glomeruli was negligible or faint also in rats with anti-
perforin antibody.
DISCUSSION
This is the first study demonstrating that the blocking of
perforin by antibody administration greatly suppresses
glomerular injury in anti-GBM GN in WKY rats. And
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Figure 2 | Detection of apoptotic cells in glomeruli by TUNEL method. (a) Although no or only a few TUNEL-positive apoptotic cells were
observed in glomeruli at day 1, (b) the number of apoptotic cells in glomeruli was significantly increased at day 3, (c) and reduced at day 7.
(d) The positive result was confirmed (e) by omitting terminal deoxynucleotidyl transferase enzyme served as negative control. Original
magnification: (a–c):  200, (d, e):  80.
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Figure 3 | Perforin protein and mRNA localization in glomerulus.
(a, b) Immunohistochemistry for perforin protein. (a) control rabbit
IgG, (b) anti-perforin antibody. Positive staining cells (arrows) appear
to be infiltrating cells. (c, d) In situ hybridization for perforin mRNA.
(c) Sense probe, (d) antisense probe. Original magnification: (a–d):
 320.
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although perforin was demonstrated in glomerular infiltrat-
ing CD8þ , the role for CD8þ as effector cells was strongly
suggested in this severe crescentic GN model. CD8þ cause
target cell apoptosis due to their cytotoxic actions, via
perforin-mediated and/or FasL-mediated mechanisms.11–15
In this study, the in vivo blocking of perforin by antibody
administration was performed, as the glomerular mRNA
expressions of perforin and granzyme B, not of Fas and FasL,
corresponded with the number of glomerular CD8þ . The
results were that the administration greatly reduced the
glomerular injury monitored by the amount of urinary
protein excretion, the frequency of crescentic glomeruli, and
the number of glomerular Mo/Mf, although the number of
glomerular CD8þ was not reduced by anti-perforin antibody
administration. The results strongly suggest that perforin in
CD8þ play a role in the course of this GN.
The persistence of CD8þ can be explained that anti-
perforin antibody may act by blocking the function of
perforin without killing CD8þ . And alternatively, even if
anti-perforin antibody administration causes the depletion of
perforin-positive mature effector CD8þ , perforin-negative
CD8þ may proliferate and differentiate. Not all of the CD8þ
express perforin. CD8þ increase the expression of perforin
according to their differentiation and maturation.20
a b
Figure 5 | Immunoelectron microscopy for perforin. Perforin
granules was demonstrated in the cytoplasmic granules of
glomerular infiltrating lymphocyte (shown by square-1). Also, perforin
released outside was demonstrated at the inner surface of the
glomerular capillaries (shown by square-2), where the structure of
endothelial cell was obscure. Original magnification: (a):  3250. (b):
 7875.
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Figure 4 | Perforin protein localization in glomerulus.
Immunohistochemistry using sequential serial sections for (a) CD8þ
and (b) perforin revealed that most of the perforin-positive cells in
glomeruli were considered to be CD8þ . The result of
immunohistochemistry for CD8þ (c) was confirmed by using isotype-
matched control mouse IgG, (d) served as negative control. (e) And
Dual-staining immunohistochemistry for perforin (brown) and CD8þ
(blue) confirmed that the perforin protein (arrow) localized in the
CD8þ . Original magnification: (a–d):  200, (e):  300.
a b
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Figure 6 | Renal histology and immunohistochemistry. (a, b)
Periodic acid-Schiff staining. Mononuclear cell infiltration and
crescent formation were mostly suppressed by anti-perforin antibody
treatment at day 7. (a) preimmune serum treatment group, (b) anti-
perforin antibody treatment group. (c, d) Immunostaining for ED-1þ
cells. The number of glomerular ED-1þ Mo/Mf was apparently
reduced by anti-perforin antibody treatment. (c) Preimmune serum
treatment group, (d) anti-perforin antibody treatment group.
(Original magnification: (a–d):  200). The result of
immunohistochemistry for ED-1 was confirmed by using isotype-
matched control mouse IgG, served as negative control (data not
shown).
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The mechanisms by which perforin causes glomerular
injury need to be discussed. From cytosolic T cells, perforin
monomers are released and inserted into the target cell
membrane, and polymerized to form a pore in a tubular
structure, through which granzymes enter the target cell and
initiate apoptosis.21 In the step of apoptosis, the contents of
the dying cell are packaged into apoptotic bodies and are
scavenged by neighboring phagocytes, so as not to be released
into the external milieu.22 In this model of anti-GBM GN,
CD8þ may be activated in the capillary lumen, recognize the
glomerular endothelial cells as the target cells, and release
perforin and granzymes from their cytoplasmic granules. The
increased number of apoptotic cells in the glomerulus
supports this hypothesis. In addition, perforin may mediate
cell death by uncontrolled influx of small molecules from the
extracellular fluid through the pore or by induction of
osmotic stress.21 Otherwise, granzymes may degrade colla-
genous components of GBM 23 and cause detachment of
endothelial cells, accompanied by the release of cytokines and
the activation of the leukocyte integrins. All of these events
may be involved in perforin/granzyme-induced direct
glomerular injury, and the part of Mo/Mf infiltrating in
glomeruli is considered to be secondary to this direct
glomerular injury induced by CD8þ .
The decreased number of glomerular Mo/Mf by anti-
perforin antibody administration can be explained by the
reduction of apoptosis and glomerular injury, and the
subsequent reduction of cytokines and chemotactic signals.
During the course of apoptosis, dying cells display ‘eat-me’
signals such as phosphatidylserine on the surface, and secrete
attraction signals such as the phospholipid lysophosphati-
dylcholine.24 Anti-perforin antibody may reduce the migra-
tion of professional phagocytes by suppression of these
signals from the dying cells.
Based on the results of our previous studies, it has been
considered that CD8þ might be involved in glomerular
injury indirectly through the action of accumulated Mo/Mf.
We have also suggested the role for Mo/Mf as effector cells
by the administration of anti-monocyte chemoattractant
protein-1 monoclonal antibody 25 and of liposome-encapsu-
lated dichloromethylene diphosphonate (liposome-MDP).26
Anti-MCP-1 monoclonal antibody administration reduced
the number of glomerular Mo/Mf by 34.7% and the amount
of proteinuria by 66.2% at day 4, without reducing the
number of glomerular CD8þ .25 Therefore, the results of this
study do not exclude the role for Mo/Mf as effectors cells.
Both CD8þ and Mo/Mf play the role of effector cells, and
they may interact with each other to cause glomerular injury.
Taken together, the pathogenesis of anti-GBM GN in
WKY rats may be proposed as follows. After binding of the
rabbit IgG to GBM, a small number of Mo/Mf first
accumulate to the glomerulus.27 Through the recognition
of the rabbit IgG Fc portion by Fcg receptors, these Mo/Mf
are stimulated to produce cytokines and chemokines, which
accumulate CD8þ into the glomerulus.10 These CD8þ play
essential roles in the initiation and the progression of the
disease. CD8þ cause glomerular injury directly by releasing
perforin/granzyme B to injure glomerular cells as shown in
this study. In addition, CD8þ injure glomerular cells
indirectly by accumulating Mo/Mf, and the Mo/Mf may
be activated in the glomerulus to release inflammatory
mediators.28 Massive accumulation of Mo/Mf at the late
stage of this model is probably mediated by cytokines
released by the action of CD8þ , which stimulate LFA-1
molecules on Mo/Mf to interact with intercellular adhesion
molecule-1 molecules on glomerular endothelial cells.29 In
consequence, both glomerular cells and GBM may be injured
by perforin/granzyme B released from the CD8þ and by
other inflammatory mediators from Mo/Mf, resulting in
marked destruction of the glomerular structure and excretion
of protein in urine.
In summary, this study has, for the first time, provided
evidence on the essential roles of perforin in CD8þ in anti-
GBM crescentic GN in WKY rats. This suggests that the
blocking of perforin might contribute to the aggressive
treatment of human severe crescentic GN in future.
MATERIALS AND METHODS
Induction of anti-GBM GN
Inbred male WKY rats aged 12–16 weeks were purchased from
Charles River Inc. (Atsugi, Kanagawa, Japan), and maintained in our
animal facility. Animal care was in accordance with the guidelines of
Niigata University (Niigata, Japan). The rats were anesthetized by
diethyl ether inhalation and euthanized by exsanguinations after the
removal of kidneys. One group of 16 rats received 25 ml (containing
325 mg of rabbit IgG) of the anti-GBM antibody per 100 g body
weight by intravenous injection as described previously.8 Four rats
each were killed at 1 h and at days 1, 3, and 7 to obtain kidneys. As a
control group, four normal rats were killed for the renal histological
examination and glomerular RNA isolation.
Anti-GBM GN in CD8þ -depleted rats
The other group of 16 rats received monoclonal antibody against rat
CD8 (MRC-OX8, IgG1, PHLS Centre for Applied Microbiology &
Research, Wiltshire, UK) at a dose of 2.8 mg of g-globulin fraction/
100 g body weight intraperitoneally and 0.6/100 g body weight
intravenously 2 days before the administration of anti-GBM
antibody to deplete CD8þ in their circulation.8 Four rats each
were killed at the same time points as the group mentioned above.
Histology and immunohistochemistry
Each kidney specimen for histology was divided; one part was fixed
in methyl-Carnoy’s solution and embedded in paraffin for histology
and immunohistochemistry, and the other part was quick-frozen in
N-hexane at 701C for cryostat sectioning. The paraffin-embedded
tissues were sectioned at a 3 mm-thickness and stained with periodic
acid-Schiff reagent for the light microscopic examination. For
immunohistochemistry, the paraffin-embedded sections were
dewaxed and incubated sequentially with normal goat serum (1:20
dilution) for blocking, a mouse monoclonal antibody against rat
Mo/Mf (ED-1; Dainippon Seiyaku Co., Tokyo, Japan, 1:500
dilution), or CD8þ (MRC-OX8; 1:200 dilution) for 1 h, and
horseradish peroxidase-conjugated goat anti-mouse Igs (EnVision,
DAKO JAPAN Co., Kyoto, Japan) for 1 h. The peroxidase reaction
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product was visualized with 0.5 mg/ml of 30-diaminobenzidine
tetrahydrochloride-0.01% hydrogen peroxide. The sections were
counterstained with hematoxylin. Cell stained with these antibodies
were counted in more than 50 gcs in each kidney under a light
microscope. The results of immunohistochemistry for ED-1 and
MRC-OX8 have been confirmed by using isotype-matched control
IgG (mouse IgG), served as negative controls. Cryostat sections
were stained with fluorescein isothiocyanate goat anti-rat IgG
(Seikagaku Kogyo Co., Tokyo, Japan) to evaluate the humoral
immune response against the rabbit IgG. The sections were
also stained with fluorescein isothiocyanate-goat anti-rabbit IgG
(Seikagaku Kogyo Co.) to evaluate the intensity of the rabbit
anti-GBM antibody localized along the GBM during the course of
the experiment.
Quantitation of glomerular RNA for perforin, granzyme A, B,
Fas, and FasL
Isolation of glomerular RNA. Glomeruli were isolated from the
renal cortex by standard sieving method, and RNA was isolated by
acid guanidinium-phenol-chloroform method.
Preparation of cDNA templates. Rat cDNA for perforin was
isolated from the cDNA library of a rat large granular lymphocyte30
by hybridization with a cDNA probe for mouse perforin (kindly
provided from Dr Ishikawa, Department of Immunology, Juntendo
University, Tokyo, Japan), and a 314 bp fragment was subcloned into
the HindIII and PstI site of pGEM-3Z (Promega Corp., Madison,
WI, USA).
For rat granzyme A, B, and rat Fas, total RNAs were isolated
from lipopolysaccharide-stimulated rat spleen and rat heart,
respectively. Then they were subjected to reverse transcription to
cDNAs and used for PCR amplifications. Primers of rat Granzyme
A, B were designed from the conserved regions of the cDNAs of
human and mouse. The sequences of sense and antisense primers for
rat granzyme A were (50-GGGAATTCTNCTGCTNATTCCTGAA-
30), and (50-GGGGATCCTTTTTAGGTAGNTGAAGGAT-30), respec-
tively, and for rat granzyme B were (50-ACTGAATTCGTGCTGACN
GCTGCTCACTG-30) and (50-ACTGGATCCAAGNGGGCCTCCAG
A-30), respectively. The sequences of sense and antisense primers for
rat Fas were (50-ACTGGATCCTGCACAGAAGGGGAGGAGTA-30)
and (50-ACTGAATTCGGTGTTGCTGGTTCGTGTGC-30), respec-
tively. The PCR cycle conditions were denaturing at 941C for 60 s,
annealing at 551C for 90 s, and elongating at 721C for 120 s through
30 cycles. The PCR products were subcloned into pGEM-4z
(Promega) for rat granzyme A and B, or pBluescriptII-SKþ
(Stratagene Co., La Jolla, CA, USA) for rat Fas, and their DNA
sequences were confirmed by an automated DNA sequencer (ABI
PRISM 310 Genetic Analyzer, PE Applied Biosystems, Tokyo, Japan).
The nucleotide sequence for the PCR-cloned rat granzyme A cDNA
(360 bp) was approximately 87% homologous with mouse cDNA
for granzyme A,31 and that for rat granzyme B cDNA (451 bp) was
approximately 83% homologous with mouse cDNA for granzyme
B.32 The nucleotide sequence for the PCR-cloned rat Fas cDNA was
240 bp.
Rat full length of cDNA for FasL in a plasmid pBL-KA15 33 was
kindly provided from Dr Nagata (Department of Genetics, Osaka
University Graduate School of Medicine, Osaka, Japan) and a 261 bp
fragment of FasL cDNA was subcloned into the KpnI and XbaI sites
of pBluescriptII-SKþ .
Rat cDNA for housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, 114 bp) was prepared as described
previously.34
Generation of 32P-labeled antisense RNA probes
The recombinant plasmids were linearized with HindIII (perforin),
EcoRI (granzyme A, B, and Fas), KpnI (FasL), and BamHI
(glyceraldehyde-3-phosphate dehydrogenase), respectively. Anti-
sense cRNA probes were prepared by in vitro transcription with
RNA polymerase T7, with the incorporation of [a-32P] UTP.
Ribonuclease protection assay. One glomerular RNA sample
was randomly selected from each group and three different sets of
the RNAs were examined by ribonuclease protection assay.35 Ten
micrograms of glomerular total RNA were hybridized with 1 105
of each 32P-labeled antisense RNA probe overnight at 501C.
Unhybridized RNA probes were digested with ribonuclease T1
(GIBCO/BRL, Gainsberg, MD, USA) and ribonuclease A (Boehrin-
ger Mannheim, Tokyo, Japan) for 1 h at 301C. The ribonucleases
were then digested with proteinase K (Promega) for 30 min at 371C.
After phenol/chloroform extraction and sodium acetate/ethanol
precipitation, the hybridized RNA probes were denatured at 851C
for 5 min and electrophoresed on a 6% polyacrylamide gel. The
dried gels were exposed to X-ray film (Fuji Photo Film Co. Ltd,
Tokyo, Japan). The blots were scanned by a scanner (ScanJet 3C,
Hewlett Packard, Sagamihara, Japan) and the density of each
protected band was quantified by a computerized image analysis
system (NIH Image, NIH, Bethesda, MD). After calibration of the
images and plotting lanes to generate the profile plots, the areas of
the peaks were measured. The data were represented as a ratio of
specific mRNA/glyceraldehyde-3-phosphate dehydrogenase mRNA
to ensure a constant quantity of mRNA in each sample.
Detection of apoptosis by TUNEL method
Cells undergoing apoptosis were identified by the TUNEL
technique, using an in situ apoptosis detection kit (ApopTag,
Intergen, Purchase, NY, USA). Paraffin-embedded tissues fixed in
methyl-Carnoy’s solution were sectioned at a 3 mm-thickness,
deparaffinized, rehydrated, and digested with proteinase K 4 mg/ml
for 15 min at room temperature. Endogenous peroxidase was
quenched by 3% hydrogen peroxidase for 10 min. After equilibra-
tion, the sections were incubated in a humidified chamber with
terminal deoxynucleotidyl transferase enzyme for 1 h at 371C.
Nucleotides labeled with digoxigenin are enzymatically added to 30-
hydroxyl DNA ends by terminal deoxynucleotidyl transferase.
Afterwards, sections were soaked in stop-wash buffer for 30 min
followed by incubation with an alkaline phosphatase-conjugated
anti-DIG antibody (1:500 dilution, Roche Diagnostics, Penzberg,
Germany) at 371C for 30 min. The signal was detected using a nitro
blue tetrazolium chloride 5-bromo-4-cloro-3-indolyl phosphate
toluidine salt (NBT/BCIP) substrate solution. The positive result
was confirmed by omitting terminal deoxynucleotidyl transferase
enzyme served as negative control.
Localization of perforin in glomerulus
In situ hybridization. In situ hybridization was performed as
described previously36 with some modifications.37 Briefly, kidneys
were perfused and prefixed with 4% paraformaldehyde. The tissues
were embedded in OCT (Miles Laboratories, Elkhart, IN, USA) and
were then frozen on dry ice. 35S-labeled antisense and sense
riboprobes were transcribed from both directions using rat perforin
cDNA cloned in pGEM-3Z. Frozen sections (4–6mm-thickness) were
fixed in 4% paraformaldehyde for 10 min on ice and deproteinated
in proteinase K solution (1mg/ml) for 10 min at room temperature.
After washing in 0.5 standard sodium citrate for 10 min,
prehybridization was performed at 421C for 2 h in 50 ml hybridiza-
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tion buffer per section. The buffer contained 10 mM dithiothreitol,
0.3 N NaCl, 20 mM Tris (pH 8.0), 5 mM ethylenediaminetetraacetic
acid, 1 Denhardt’s, 10% dextran sulfate, and 50% formamide. Ten
microliter of hybridization buffer with radiolabeled probe
(3 105 c.p.m. per section) was added directly into the bubble of
prehybridization solution covering the sections. Hybridization was
performed at 551C overnight. After washing in 2 standard sodium
citrate, slides were immersed in RNase digestion buffer (20 mg/ml
RNase A) at room temperature for 30 min. The slides were
then washed twice in 0.5 standard sodium citrate without
ethylenediaminetetraacetic acid and b-ME for 10 min. Following
dehydration, the slides were dried. After autoradiography for 3 days,
the slides were dipped in Kodak NTB2 nuclear emulsion (Eastman
Kodak Co., Rochester, NY) diluted 1:1 with water at 421C.
Exposure was performed at 41C in the dark for 4 weeks before
development.
Dual-staining immunohistochemistry for CD8 and perfor-
in. The paraffin-embedded sections were dewaxed and used. At
first, sequential serial sections were prepared for the purpose of
comparing the location of glomerular CD8þ with that of perforin-
positive cells. The results were confirmed by using isotype-matched
control IgG (mouse or rabbit IgG, respectively), served as negative
controls. For dual-staining immunohistochemistry, endogenous
peroxidase was quenched by 3% hydrogen peroxidase for 10 min.
Slides were incubated sequentially with normal goat serum for
blocking, a mouse monoclonal antibody against rat CD8þ for 1 h,
biotinylated anti-mouse IgG (Vector labs, Burlingame, CA, USA) for
30 min, followed by alkaline phosphatase streptavidin (Vector labs)
for 30 min, and the sections were visualized with a nitro blue
tetrazolium chloride/5-bromo-4-cloro-3-indolyl phosphate tolui-
dine salt substrate solution. The second primary antibody, a rabbit
polyclonal antibody against rat perforin (Dainippon Seiyaku Co.,
1:20 dilution), was applied next after heating for 10 min by
microwave in 0.01 M sodium citrate buffer (pH 6.0). Slides were
then incubated overnight at 41C. After washing in phosphate-
buffered saline, horseradish peroxidase-conjugated goat anti-rabbit
Igs (EnVision) was applied for 30 min. The peroxidase reaction
product was visualized with 0.5 mg/ml of 30-diaminobenzidine
tetrahydrochloride-0.01% hydrogen peroxide.
Immunoelectron microscopy. Immunoelectron microscopic
observations of kidneys were performed as reported previously.38,39
In brief, 1 mm3 kidney blocks were placed in the paraformaldehyde-
lysine-periodate fixative for 4 h at 41C, hydrated, and then
embedded in hydrophilic methacrylate resin. The ultrathin sections
collected on nickel grids were stained with the immunogold
technique.
In vivo blocking of perforin in anti-GBM GN
Preparation of anti-perforin antibody for blocking. A neutraliz-
ing rabbit antibody against rat perforin was generated using a
recombinant perforin peptide expressed by Escherichia coli. The
antibody recognized perforin expressed in transformed African
green monkey kidney fibroblast cell line (COS-7) by immunohis-
tochemical staining and could block perforin-mediated cytotoxicity
of cytotoxic T cells in vitro, which was tested by 51Cr release
assay.40,41 Briefly, 51Cr-labeled target cells (P815/S) were incubated
with effector cells (6C2, clones of CTL line) for 4 h, and
supernatants were removed and measured radioactivity of released
51Cr. The radioactivity was counted by a g-counter. The percent-
specific lysis was calculated using the following formula:
100 (ab/cb), where a is the radioactivity in the supernatant
of target cells mixed with effector cells (¼ experimental release), b is
the radioactivity in the supernatant of target cells incubated without
effector cells (¼ spontaneous release), and c is the radioactivity in the
supernatant after complete lysis of target cells with 2% Triton X-100
(¼maximum release). To demonstrate perforin-dependent cyto-
toxicity, anti-perforin antibody (5, 10, or 20 ml), or control rabbit
IgG (20 ml) were added to mixtures of effector cells and labeled
target cells in the assay. And as a controlled experiment, 6C2 clones
were pretreated with concanamycin A (CMA; Wako Pure Chemical
Industries, Osaka, Japan) for 2 h and mixed with target cells (A20).
Concanamycin A was reported to inhibit perforin-dependent
cytotoxicity mostly due to accelerated degradation of perforin by
an increase in the pH of lytic granules.42 The result was depicted as
Table 1. The percent specific lysis by effector cells was shown to be
inhibited by addition of anti-perforin antibody in a dose-dependent
manner.
Administration of anti-perforin antibody. One group of five
rats was given anti-perforin antibody (1 ml/rat) for 5 successive days
from 1 day after anti-GBM antibody administration. As a control,
the other group of five rats was given preimmune serum (1 ml/rat)
instead of anti-perforin antibody. All rats were killed at day 7 for
histological analysis.
Urine samples were collected for 24 h before the induction of the
GN and at days 3, 5, and 7. The amounts of protein excreted in the
urine were determined by using a protein assay kit (Nippon Bio-Rad
Laboratories, Tokyo, Japan).
Each kidney specimen for histology was divided for paraffin or
cryostat sectioning, and examined for light microscopy and
immunohistochemistry as described above.
Statistical analysis
The data were expressed as the mean71SD. Statistical significance
was analyzed by Mann–Whitney’s U-test. Differences with Po0.05
were considered statistically significant.
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% specific
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20 ml/well 10 84
A20 Nontreatment 10 78
CMA 10 31
CMA, concamamycin A.
The percentage of target cell lysis increased as the ratio of effector cells/target cells
increased. In the case of anti-perforin antibody treatment, the target cell lysis by
effector cells was suppressed in a dose-dependent manner, which verified the
perforin blocking effect of this antibody. As a control, rabbit IgG was shown to have
no effects on suppressing the lysis via perforin blocking. CMA was also shown to
suppress lysis mostly due to accelerated degradation of perforin.
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